Sourasky Medical Center (Ichilov)
Sourasky Medical Center (Ichilov)
Izrael, Tel Awiw
Ofer Merimsky
41 lat doświadczenia
akredytacje :
Akredytacje :
Usunięcie nowotworu wątroby w Izraelu kosztuje zazwyczaj od $22,000 do $40,000. Ostateczna cena zależy od metody chirurgicznej oraz wielkości guza. Istotna jest także lokalizacja, w tym Tel Awiw, Jerozolima lub Hajfa. W Polsce pacjenci płacą zwykle $30,000 za podobne zabiegi. Izrael oferuje średnie oszczędności na poziomie 27%. Typowe koszty obejmują diagnostykę przedoperacyjną, honorarium chirurga, znieczulenie oraz 5–10 dni pobytu w szpitalu.
Opinia ekspercka Bookimed: Wybór specjalisty, takiego jak dr Menahem Ben-haim z Sourasky Medical Center (Ichilov), daje dostęp do wiedzy cenionej przez Forbes. Choć najlepsze kliniki w Tel Awiwie mają wyższe ceny podstawowe, osiągają 90-procentową skuteczność leczenia onkologicznego. Placówki takie jak Assuta Medical Center oferują możliwość wyboru konkretnego chirurga. Taka elastyczność zapewnia wysoką jakość opieki w ośrodkach akredytowanych przez JCI bez długiego oczekiwania na termin.
Dlaczego pacjenci wybierają Izrael do usunięcia raka wątroby?
Skorzystaj z zaawansowanych rozwiązań usuwania raka wątroby w zaufanych klinikach .
| Izrael | Turcja | Austria | |
| Resekcja w przypadku raka wątroby | od $22,000 | od $10,800 | od $40,000 |
| SIRT wątroby | od $24,500 | od $24,000 | od $17,000 |
| Resekcja wątroby | od $27,500 | od $11,700 | od $35,000 |
Day 1 - Arrival
Day 2 - Pre-Operation
Day 3 - Operation
Day 4 - Post-Operation
Day 5 to Day 14 - Recovery in the Hospital
Week 3 to Week 8 - Rehabilitation at Home
Please note that this is a general guide, individual cases may vary.
Kierownik Oddziału Onkologii Tkanek Miękkich i Kości w Centrum Medycznym Sourasky – prof. Merimsky specjalizuje się w złożonych przypadkach raka wątroby.
Dr. Arnon Nagler is an internationally recognized hematologist and bone marrow transplant expert. He is a Professor of Medicine at Tel Aviv University. He is Director Emeritus of Hematology & Bone Marrow Transplantation and the Cord Blood Bank at Sheba Medical Center. He earned his M.D. from the Hebrew University–Hadassah and an M.Sc. in hematopoiesis from Tel Aviv University. He completed postdoctoral training at Stanford. He is board certified in internal medicine and hematology.
He has more than 35 years of experience. He pioneered reduced‑intensity allogeneic transplant protocols for malignant and non‑malignant diseases. He founded Israel’s first public cord blood bank. He performed the country’s first cord blood transplants.
He has held international leadership roles. He served as Chair and Co‑Chair of the ALWP of the EBMT. He was a vice‑chair and long‑term member of EBMT committees. He served on the board of NetCord/EuroCord and as treasurer. He is a frequent invited speaker. He has published widely in journals such as Blood and Leukemia. He has led major clinical trials as a principal investigator and held editorial roles. He has received multiple awards for innovation and clinical excellence.
Prof. Ido Nachmany heads the Second Surgical Department at Sheba Medical Center. He specializes in HPB and robotic surgery for diseases of the liver, pancreas, and bile ducts, and for gastrointestinal neuroendocrine tumors. He also performs adrenal, spleen, and stomach surgery. Forbes listed him among Israel’s top physicians.
He advances minimally invasive robotic and laparoscopic techniques. The aim is better precision and faster recovery.
Credentials: Senior Lecturer at Tel Aviv University. Member of ASTS and IHPBA. Completed HPB and abdominal transplant fellowships at the Thomas E. Starzl Transplantation Institute. Board certified in General Surgery (Israel), Abdominal Organ Transplantation (ASTS), and HPB Surgery (University of Pittsburgh). He has published in Cancer Research, the Journal of the American College of Surgeons, and the European Journal of Surgical Oncology.
Dr. Almog Ben-Yaacov is an Attending Surgeon in the Department of General and Oncological Surgery (Surgery C) at Sheba Medical Center. He specializes in cytoreductive surgery (CRS) with hyperthermic intraperitoneal chemotherapy (HIPEC). His clinical focus includes gastric cancer, sarcoma, and complex colorectal malignancies. Since 2018, he has performed more than 200 HIPEC procedures.
MD, Semmelweis University, 2006, with honors. Training in cardiothoracic surgery at Sheba Medical Center. Residency in general surgery at Montefiore (Albert Einstein) and at Rabin (Beilinson). Board-certified in General Surgery and in Surgical Oncology.
Advanced training includes ESSO-certified HIPEC in Hamburg. Microwave liver ablation in Reims. NanoKnife at King’s College London. Advanced surgical oncology at Memorial Sloan Kettering (2019). His publications cover CRS+HIPEC outcomes and Hartmann’s reversal.